好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2008 Annual Meeting | Therapeutic Poisoning: Immunosuppressive Therapy for Non-neoplastic Neurologic Disease

Saturday 04/19/08
09:00 AM - 12:45 PM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
AM Half-Day Course
Michael Glantz, MD, FAAN
Participants should be able to describe the currently available classes of immunosuppressive and myelosuppressive agents, their neurologic and non-neurologic toxicities, and the practical aspects of their administration; explain the rationale and optimum strategies for the use of these agents in a wide spectrum of primary and secondary nervous system disorders, including demyelinating and neuromuscular diseases; establish a safe and efficient office-based program for the use of immunosuppressive and myelosuppressive therapies in patients with nervous system diseases; develop algorithms for patient selection, informed consent, treatment, and monitoring; and apply standardized metrics for assessing treatment outcome.
No CME available
Patient Care & Procedural Skills, Professionalism, Medical Knowledge, Systems-based Practice
Advanced
Practitioner, Fellow, Academician, Resident, Nurse
Event Timeline
09:00 AM - 09:20 AM Immunosuppressive Therapy for Neuromuscular Disease: How I Do It
Mark S. Freedman, MD, FAAN
09:20 AM - 09:40 AM Immunosuppressive Therapy for Neuromuscular Disease: How I Do It
Marinos C. Dalakas, MD, FAAN
09:40 AM - 10:15 AM Immunosuppression in the Office: Making Poisons Palatable
Michael Glantz, MD, FAAN
10:15 AM - 10:50 AM Ethical Immunosuppression: Doing the Math and Explaining the Results
Samuel Wiebe, MD
10:50 AM - 11:05 AM Break
11:05 AM - 11:40 AM Immunosuppression in the Office: How to Be Safe and Efficient
Camilo E. Fadul, MD, FAAN
11:40 AM - 12:05 PM Case Presentations: Demyelinating Disease
Mark S. Freedman, MD, FAAN
12:05 PM - 12:30 PM Case Presentations: Neuromuscular Disease
Marinos C. Dalakas, MD, FAAN
12:30 PM - 12:45 PM Questions and Answers
Faculty Disclosures
Marinos C. Dalakas, MD, FAAN Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols, . Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx,. Dr. Dalakas has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Dysimmune Diseases Foundation. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Serono. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octapharma. Dr. Dalakas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Kyverna. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ARGENX. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Therapeutic Advances in Neurology (TAND). Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medlink.
Mark S. Freedman, MD, FAAN Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Actelion(Janssen/J&J). Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BiogenIdec. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS/Celgene. Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Inc. Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Actelion (Janssen/J&J). Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Atara Biotherapeutics. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer Healthcare. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for BiogenIdec. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Clene Nanomedicine. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GRI Bio. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Magenta Therapeutics. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Dr. Freedman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi Genzyme. Dr. Freedman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. The institution of Dr. Freedman has received research support from Sanofi Genzyme.
Michael Glantz, MD, FAAN No disclosure on file
Camilo E. Fadul, MD, FAAN No disclosure on file
Samuel Wiebe, MD Dr. Wiebe has a non-compensated relationship as a Past President with International League Against Epilepsy that is relevant to AAN interests or activities.